U.S. markets closed
  • S&P Futures

    3,932.75
    -4.00 (-0.10%)
     
  • Dow Futures

    33,608.00
    -17.00 (-0.05%)
     
  • Nasdaq Futures

    11,492.50
    -17.00 (-0.15%)
     
  • Russell 2000 Futures

    1,806.00
    -2.00 (-0.11%)
     
  • Crude Oil

    72.75
    +0.74 (+1.03%)
     
  • Gold

    1,794.70
    -3.30 (-0.18%)
     
  • Silver

    22.78
    -0.14 (-0.60%)
     
  • EUR/USD

    1.0498
    -0.0017 (-0.16%)
     
  • 10-Yr Bond

    3.4080
    -0.1050 (-2.99%)
     
  • Vix

    22.68
    +0.51 (+2.30%)
     
  • GBP/USD

    1.2183
    -0.0022 (-0.18%)
     
  • USD/JPY

    137.2350
    +0.7110 (+0.52%)
     
  • BTC-USD

    16,835.33
    -197.92 (-1.16%)
     
  • CMC Crypto 200

    395.22
    -6.81 (-1.69%)
     
  • FTSE 100

    7,489.19
    -32.20 (-0.43%)
     
  • Nikkei 225

    27,526.04
    -160.36 (-0.58%)
     

What You Need To Know About Larimar Therapeutics, Inc.'s (NASDAQ:LRMR) Investor Composition

The big shareholder groups in Larimar Therapeutics, Inc. (NASDAQ:LRMR) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that have been privatized tend to have low insider ownership.

Larimar Therapeutics is a smaller company with a market capitalization of US$245m, so it may still be flying under the radar of many institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Larimar Therapeutics.

View our latest analysis for Larimar Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Larimar Therapeutics?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

We can see that Larimar Therapeutics does have institutional investors; and they hold a good portion of the company's stock. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Larimar Therapeutics, (below). Of course, keep in mind that there are other factors to consider, too.

earnings-and-revenue-growth
earnings-and-revenue-growth

Our data indicates that hedge funds own 33% of Larimar Therapeutics. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Looking at our data, we can see that the largest shareholder is Deerfield Management Company, L.P. with 33% of shares outstanding. The second and third largest shareholders are RA Capital Management, L.P. and CHI Advisors LLC, with an equal amount of shares to their name at 8.6%.

To make our study more interesting, we found that the top 3 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.

While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Larimar Therapeutics

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Shareholders would probably be interested to learn that insiders own shares in Larimar Therapeutics, Inc.. In their own names, insiders own US$3.0m worth of stock in the US$245m company. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public holds a 14% stake in Larimar Therapeutics. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.

Private Equity Ownership

With an ownership of 17%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Sometimes we see private equity stick around for the long term, but generally speaking they have a shorter investment horizon and -- as the name suggests -- don't invest in public companies much. After some time they may look to sell and redeploy capital elsewhere.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 4 warning signs for Larimar Therapeutics you should be aware of, and 1 of them shouldn't be ignored.

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.